Search Results - subject:"Roflumilast"

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

Samyshkin, Yevgeniy; Kotchie, Robert; Mörk, Ann-Christin; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 69-82

The addition of roflumilast to LABA in the treatment of patients with severe-to-very severe COPD reduces the rate of …

Persistent link: https://www.econbiz.de/10010993843

Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom

Samyshkin, Yevgeniy; Kotchie, Robert W.; Mörk, Ann-Christin - In: The European journal of health economics : HEPAC ; … 15 (2014) 1, pp. 69-82

Persistent link: https://www.econbiz.de/10010235895

A 1-Year Prospective Cost-Effectiveness Analysis of Roflumilast for the Treatment of Patients with Severe Chronic Obstructive Pulmonary Disease

Rutten-van Molken, Maureen P.M.H.; van Nooten, Floortje E. - In: PharmacoEconomics 25 (2007) 8, pp. 695-711

Rationale: Roflumilast is an oral, once-daily phosphodiesterase IV (PDE4) inhibitor under investigation for chronic … obstructive pulmonary disease (COPD). This study investigated the cost effectiveness of roflumilast in patients with severe to … roflumilast 500mug once daily (n = 761) or placebo (n = 753). Patients in both treatment groups were allowed to receive active …

Persistent link: https://www.econbiz.de/10005449249